Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and SAGE Therapeutics (NASDAQ: SAGE)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nektar Therapeutics (NASDAQ: NKTR) and SAGE Therapeutics (NASDAQ: SAGE) with bullish sentiments.

Nektar Therapeutics (NASDAQ: NKTR)

Roth Capital analyst Michael Higgins reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) yesterday and set a price target of $32.50. The company’s shares opened today at $21.03.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -14.7% and a 34.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $28.38, representing a 35.0% upside.

In a report issued on August 16, Jefferies also reiterated a Buy rating on the stock with a $23 price target.
SAGE Therapeutics (NASDAQ: SAGE)

In a report released today, Cory Kasimov from J.P. Morgan assigned a Buy rating to SAGE Therapeutics (NASDAQ: SAGE). The company’s shares opened today at $82.25, close to its 52-week high of $90.44.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.6% and a 41.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.

SAGE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $97.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.